Virginia Medicaid (Cardinal Care) GLP-1 Coverage (2026): Pattern #18 — Conditional Coverage With Highest Published BMI Threshold in Series (BMI > 40 Floor + BMI > 37 + Comorbidity) + Two-Level Step Therapy (Phentermine-then-Saxenda-then-Wegovy/Zepbound) + Active 2026 BALANCE-Conditional Legislation (SB30 Item 291 #5s / HB30 Item 291 #9h) + Forced Single-PBM Consolidation by July 1, 2026 (HB 2610 / SB 875) + 12VAC30-50-520 Unamended Since 1999 + Removed-GLP1-Exclusion Legislative History YMYL Trap

TL;DR — Virginia Cardinal Care GLP-1 coverage at a glance

Pattern #18 — Where Virginia fits in the 50-state series

This is the 18th installment in this series after Texas (#1), California (#2), New York (#3), Florida (#4), Illinois (#5), Ohio (#6), Pennsylvania (#7), Georgia (#8), North Carolina (#9), New Jersey (#10), Michigan (#11), Arizona (#12), Tennessee (#13), Washington (#14), Massachusetts (#15), Washington D.C. / Indiana (#16), and others in the series.

Virginia’s pattern is unique: conditional coverage with the highest published BMI threshold in the series, nested two-level step therapy, and mid-flight PBM consolidation. No other state in the first 17 has applied a numeric BMI >40 floor as a weight-management coverage gate in any operationally-binding clinical-policy document. Other covering states (NC, TN, MA Phase 1, WA MACE pathway) use BMI thresholds aligned with the FDA label (≥27 with comorbidity or ≥30).

Key distinguishing comparisons:

• Vs. NC (#9) — closest analog on coverage status: NC reinstated in December 2025 at BMI ≥30 (FDA-label-aligned). Virginia’s BMI >40 floor is dramatically more restrictive and reflects a budget-rider compromise, not a P&T clinical-policy choice. NC has had an explicit on-off-on cycle within 14 months; VA has been in continuous coverage-with-restrictions posture since July 1, 2024.
• Vs. TN (#13) — most permissive AOM panel: TennCare covers GLP-1s at FDA-label-aligned BMI >30 / BMI >27+comorbidity with no separate Saxenda step-therapy gate and a 10-AOM no-PA panel. Virginia’s BMI >40 floor and two-level step-therapy represent the opposite end of the coverage spectrum among covering states.
• Vs. PA (#7) — policy-reversal state: PA terminated coverage January 1, 2026. Virginia has not terminated — but SB30 Item 291 #5s contains an implicit termination trigger if no manufacturer arrangement achieves the $245/month price target. Both outcomes remain open.
• Vs. WA (#14) — indication-anchored: WA covers Wegovy for MACE only (not chronic weight management). Virginia covers both: MACE (BMI ≥27, age ≥45, cardiologist-prescribed) AND chronic weight management (BMI >40 / >37+comorbidity).

KFF’s January 2026 tracker classifies Virginia as one of 13 state Medicaid programs covering GLP-1s for obesity under fee-for-service as of January 2026.^[15] The YMYL trap is that the binary “covers” classification masks the BMI >40 floor and two-level step therapy that make this the most operationally restrictive positive-coverage state in the series.

BMI >40 floor — strictly more restrictive than the FDA label

The operative GLP-1 coverage criteria for chronic weight management are in Section 4 of the Virginia DMAS SA Form: Weight-Loss Management (Effective 07/31/2025).^[1] Verbatim:

“4. For GLP-1 receptor agonists indicated for weight loss (Wegovy/Saxenda [min age 12], Zepbound [min age 18]):
• BMI >40 kg/m² if no applicable risk factors; OR
• BMI >37 kg/m² with one or more of the following risk factors: dyslipidemia, hypertension, or type 2 diabetes”

The FDA Wegovy (semaglutide) label authorizes use in adults with initial BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity. The FDA Zepbound (tirzepatide) label uses the same ≥30 / ≥27+comorbidity thresholds. Virginia Medicaid’s BMI >40 floor is therefore 13 BMI units above the FDA Wegovy/Zepbound label threshold for a patient with a comorbidity.

This distinction is clinically significant. A patient with BMI 32 and hypertension would qualify for Wegovy under the FDA label, and would qualify for coverage under NC Medicaid (BMI ≥27+comorbidity), TN Medicaid (BMI >27+comorbidity), and the standard BALANCE Model criteria. They would NOT qualify under Virginia Cardinal Care, which requires BMI >37 even with a qualifying comorbidity.

For context: the non-GLP-1 weight-loss drugs (phentermine, orlistat, phendimetrazine) are gated at the FDA-label-aligned BMI ≥30 / BMI ≥27+comorbidity threshold under Section 1 of the same SA form. The GLP-1 threshold is therefore not only more restrictive than the FDA label but also more restrictive than the threshold for the traditional weight-loss drugs the member must fail first.

The legal source for the BMI >40 floor is the 2024 Appropriation Act, HB30 Conference Report Item 288 #12c^[4], as modified by floor amendment 288 #3h (discussed below), and operationalized in State Plan Amendment SPA 25-004 filed March 17, 2025.^[6]

Two-level step therapy — traditional drug, then Saxenda, then Wegovy or Zepbound

The step-therapy architecture in Virginia is nested: not one step-therapy gate but two sequential gates before a member can access Wegovy or Zepbound.

Step 1 — Non-GLP-1 weight-loss drug failure. The SA form requires verbatim:

“Member has tried and failed one of the non-GLP1 weight-loss medications; OR Member is intolerant to all non-GLP1 weight-loss medications”^[1]

The Definitions of Accepted Drug Trial table specifies:

“Benzphetamine, diethylpropion, phendimetrazine, phentermine, phentermine/topiramate | 3 month trial without a weight loss of 10lbs
Orlistat | 6 month trial without a weight loss of 10lbs”^[1]

Step 2 — Saxenda-specific failure. The Virginia PDL Common Core Formulary (Version 01/01/2025 v7) carries the annotation:

“♦ The selected GLP-1 Receptor Agonist is Saxenda”^[8]

This annotation operationalizes the SA form’s requirement that the member “tried and failed the selected product as indicated on the PDL.” Because Saxenda is the designated step-therapy GLP-1, a member must complete a 6-month Saxenda trial without ≥5% body weight reduction before accessing Wegovy or Zepbound. The trial definition:

“GLP-1 Receptor Agonist | 6 month trial without a body weight reduction of 5%”^[1]

The full sequence for a member seeking Wegovy or Zepbound under Virginia Cardinal Care:

1. Meet the BMI >40 (or BMI >37+comorbidity) threshold.
2. Fail phentermine, phendimetrazine, benzphetamine, diethylpropion, or phentermine/topiramate — 3 months without 10 lb loss (or be intolerant to ALL non-GLP-1 options).
3. Fail Saxenda (liraglutide 3 mg) — 6 months without ≥5% body weight reduction.
4. Then submit the Weight-Loss Management SA form, with all criteria documented by a prescribing physician.

This is a sequential-access regime, not a parallel-access regime. A prescriber cannot skip to Wegovy or Zepbound even if those drugs are clinically superior for a given patient — the step-therapy must be documented. The only exception is intolerance to all non-GLP-1 options (which bypasses Step 2 only; the Saxenda step still applies if the member is not intolerant to GLP-1s generally).

Authorization duration once approved: 6 months initial for GLP-1 RAs; renewal at 6 months if the member achieves ≥5% body weight reduction vs. most recent authorization. Renewals stop when BMI falls below 25.

The removed-exclusion YMYL trap — what December 2024 news coverage got wrong

The original 2024 Appropriation Act Conference Report Item 288 #12c contained language limiting weight-loss drug coverage to “traditional weight loss medication prescribed for weight loss as FDA approved, excluding Glucagon-like peptide-1 drugs and any other newer weight loss medications”^[4] — which would have categorically excluded GLP-1s from the weight-loss coverage pathway.

Before final passage, HB30 floor amendment 288 #3h was applied. The floor amendment is titled “(DMAS) Eliminate New Limit for Weight Loss Medications in Medicaid” and was Floor Approved.^[5] It removed the categorical GLP-1 exclusion clause. The enacted language retained only the BMI >40 / BMI >37+comorbidity threshold for ALL weight-loss drugs, including GLP-1s.

The result: Virginia Cardinal Care does cover GLP-1s for chronic weight management — it does not categorically exclude them. The coverage is conditioned on the BMI threshold and step-therapy gate, but it is real coverage.

Any secondary source citing the December 2024 budget debate to imply that Virginia excludes GLP-1s should be read with this legislative history in mind. The operative rule for a member filing a PA today is the enacted version (BMI >40 with step therapy), not the original draft’s categorical exclusion. Rely only on the current SA form (Effective 07/31/2025) for clinical-decision purposes.

12VAC30-50-520 — unamended since September 1, 1999

The published Virginia Administrative Code provision governing weight-loss drug coverage is 12VAC30-50-520 Section A. The verbatim text as of May 10, 2026:^[7]

“12VAC30-50-520. Drugs or drug categories which are not covered.
A. Agents when used for anorexia or weight gain. Coverage of anorexiants for other than weight loss requires medical justification. FDA-approved drug therapies and agents for weight loss, when preauthorized, will be covered for recipients who meet the strict disability standards for obesity established by the Social Security Administration in effect on April 7, 1999, and whose condition is certified as life threatening, consistent with Department of Medical Assistance Services’ medical necessity requirements, by the treating physician.”^[7]

The historical notes are unambiguous:

“Derived from VR460-03-3.1105, eff. April 1, 1993; amended, Virginia Register Volume 13, Issue 18, eff. July 1, 1997; Volume 15, Issue 23, eff. September 1, 1999.”^[7]

This regulation has not been formally re-promulgated since September 1, 1999. The 1999 text references “the strict disability standards for obesity established by the Social Security Administration in effect on April 7, 1999” as the coverage trigger — a standard that predates the modern BMI-based obesity classification frameworks used in clinical practice today.

The 2024 budget rider’s BMI >40 / BMI >37+comorbidity rule was implemented via the State Plan Amendment process (SPA 25-004, filed March 17, 2025)^[6], NOT via formal amendment of 12VAC30-50-520. DMAS was authorized to “promulgate emergency regulations to implement this amendment within 280 days” of enactment under the 2024 budget rider^[4] — but the regulation has not been formally updated in the published VAC.

MASH SA Form — new as of October 16, 2025

The Virginia DMAS GLP-1 RA for MASH SA Form was newly added at the October 16, 2025 P&T Committee meeting, per the verbatim action line in the draft minutes:

“New SA form for GLP-1 Receptor Agonists for Metabolic Dysfunction-Associated Steatohepatitis (MASH) with revisions requested by the board members”^[14]

The form’s revision date (Revised: 10/16/2025) confirms the P&T action date. The verbatim coverage criteria:^[3]

“The member 18 years of age or older; AND
The member has a diagnosis of MASH with results of baseline liver biopsy or noninvasive tests demonstrating the presence of stage F2 or F3 fibrosis by at least one of the following:
• Liver biopsy; OR
• Noninvasive tests (such as transient elastography, Fibroscan, or magnetic resonance elastography) performed within the last 6 months; AND
The member has a BMI ≥ 18.5 kg/m²; AND
The provider attests that the member received individualized healthy lifestyle counseling; AND
The member does not have an A1C of >9.5%; AND
The member does not have known or suspected excessive consumption of alcohol according to the CDC’s guidance; AND
The member does not have hepatic decompensation or a MELD score of >12 at screening; AND
The member does not have pancreatitis, acute suicidal behavior/ideation, personal or family history of medullary thyroid cancer or multiple endocrine neoplasia 2 syndrome. AND
The member is not concurrently on another GLP-1 receptor agonist”^[3]

The prescriber must be “a hepatologist or gastroenterologist or other provider specializing in liver disease.” Initial authorization: 6 months; renewal: 12 months.

Several features are notable in the series context. The BMI ≥18.5 threshold is the lowest BMI floor of any Virginia GLP-1 SA form — consistent with the FDA Wegovy MASH label, which sets no specific BMI floor for the MASH indication. The F2/F3 fibrosis requirement is the same as the FDA Wegovy MASH label. North Carolina’s MASH pathway is broader (F1/F2/F3; FIB-4 accepted). The MELD ≤12 cap reflects the FDA label’s “no prior hepatic decompensation” criterion.

The MASH pathway is completely independent from the BMI >40 weight-management threshold. A Virginia Cardinal Care member with MASH and BMI 22 who meets all other criteria qualifies under the MASH pathway. This is one of three separate SA-form pathways — weight-loss management, MACE/cardiovascular, and MASH — that a prescriber must correctly identify at the time of PA submission.

Active 2026 Virginia legislation — three amendments, all Committee Approved

Virginia is mid-session in the 2026–2028 biennial budget (SB30/HB30). Three amendments related to GLP-1 coverage are at Committee Approved status as of May 10, 2026. None are enacted law. Outcomes are not predicted here.

SB30 Item 291 #5s — “Modify Weight Loss Drug Coverage”

The most structurally significant amendment. It creates a price-conditional threshold-reduction pathway tied to the CMS BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth), which CMS Innovation Center launched in January 2026 with state opt-in available May 2026 through January 1, 2027.

“Primary Directive: DMAS must evaluate pharmaceutical programs targeting glucagon-like peptide-1 receptor agonist cost reduction and implement the arrangement yielding greatest savings at ‘$245 or less’ per unit.
Three Implementation Pathways:
1. BALANCE Model Option: If selected, cover weight loss medications when individuals have:
• BMI ≥ 35, OR
• BMI ≥ 30 plus hypertension/diabetes/kidney disease/heart failure, OR
• BMI ≥ 27 plus pre-diabetes/cardiovascular disease/sleep apnea
2. Alternative Arrangement: Implement coverage per specific contracting terms
3. Fallback Option: If no program achieves cost targets, cover only when:
• BMI > 40, OR
• BMI > 37 plus weight-related comorbidities”^[10]

Virginia has not announced BALANCE Model participation as of May 10, 2026. The $245/month price target in SB30 Item 291 #5s is structured to align with anticipated BALANCE Model pricing. If no arrangement achieves the target, the current BMI >40 / BMI >37+comorbidity rule continues unchanged.

HB30 Item 291 #9h — “Modify Medicaid Criteria for Weight Loss Drugs”

A narrower amendment that modifies the existing rule in three ways:

“Modifies BMI threshold language from ‘greater than’ to ‘greater than or equal to’ (lines 13-15);
Adds obstructive sleep apnea as a coverage criterion when BMI ≥ 27;
Removes exclusions for ‘GLP-1 drugs and any other newer weight loss medications’;
Price Ceiling: ‘DMAS shall not list on the Common Core Formulary, any drug in the Common Core Formulary class which contains GLP-1 receptor agonist medications...if the net price for a one-month supply exceeds $245’”^[11]

The “greater than” to “greater than or equal to” shift for BMI 40 is a small but legally meaningful change — it would include members at exactly BMI 40.0. The OSA addition at BMI ≥27 would create a new comorbidity pathway well below the current BMI >37 comorbidity floor. The $245 price cap would function as an automatic PDL-removal trigger if manufacturers do not negotiate to that net price.

As of May 10, 2026, HB30 Item 291 #9h and SB30 Item 291 #5s are headed for budget-conference reconciliation. The two versions are structurally different — SB30 is conditional on BALANCE participation; HB30 adds OSA at a fixed threshold and imposes a price cap — so the conference outcome is not predictable from either version alone.

SB30 Item 75 #1s — “State Health Plan Coverage of Weight Loss Drugs” (DHRM — separate from Medicaid)

“The Department of Human Resource Management (DHRM) shall, through its contracted actuary, evaluate pharmaceutical manufacturer programs and other contracting arrangements available to self-insured health insurance programs that are intended to reduce the costs of glucagon-like peptide-1 (GLP-1) receptor agonists and related therapies...DHRM may impose increased cost-sharing for GLP-1 drugs prescribed for weight loss and add additional restrictions on GLP-1 drugs [if savings cannot be achieved]”^[12]

Critical distinction: SB30 Item 75 #1s applies to the Virginia state employee health plan (DHRM) — NOT to Cardinal Care Medicaid. The state employee plan covers approximately 150,000 active state employees, dependents, retirees, and local political subdivision employees. It is administered by the Department of Human Resource Management, separate from DMAS. Any actions taken by DHRM under this amendment do NOT change Cardinal Care Medicaid coverage. The two programs have separate boards, separate PBM contracts, and separate benefit structures.

Forced PBM consolidation by July 1, 2026 — the first mid-consolidation state in this series

HB 2610 / SB 875 (2025 session, signed by Governor Youngkin) is the most structurally unusual feature of the Virginia Cardinal Care landscape. Per the NCPA newsroom:

“In 2025, the General Assembly passed HB 2610 requiring DMAS to contract with a single third-party PBM for all Medicaid populations, with DMAS having a relatively short timeline to procure the single PBM and have a contract in place by July 1, 2026. The single PBM is solely contracted with the state Medicaid agency and operates as a PAHP (Prepaid Ambulatory Health Plan), which provides the pharmacy benefit to all members enrolled in the managed care program. The health plans are not at risk for the pharmacy benefit. Projected savings: at least $39 million annually.”^[13]

The Virginia Medicaid Pharmacy Benefit Manager Study (HD8, 2025 Appropriation Act Item 292.MM.2.) examined three contracting options: a single PBM with MCOs At-Risk; a single PBM with MCOs Non-Risk; and a single PBM At-Risk (the PAHP model). The procurement is in flight as of May 10, 2026.

Implications for members during the transition window: Until July 1, 2026, pharmacy benefits are split across six separate PBM relationships:

Post-consolidation (July 1, 2026 and after), a single PAHP PBM will adjudicate pharmacy claims for all Cardinal Care members — FFS and MCO-enrolled alike. This is structurally analogous to NC’s Prime Therapeutics FFS PBA implementation (announced November 2023 contract award), but Virginia is going further by consolidating MCO pharmacy as well as FFS.

What does not change at consolidation: the BMI >40 / BMI >37+comorbidity coverage criteria and step-therapy requirements are established by the 2024 Appropriation Act budget rider and the SA forms, not by the PBM contract. A PBM consolidation does not expand or contract eligibility thresholds — only legislative or regulatory action can do that.

T2D vs. weight-loss distinction — a different formulary class

GLP-1 receptor agonists prescribed for type 2 diabetes are covered through an entirely separate formulary pathway. The Virginia PDL Common Core Formulary maintains a “Diabetes Hypoglycemics: Injectable and Oral Incretin Mimetics CLOSED CLASS” with the following structure per the October 1, 2024 distribution:^[8]

“Preferred Agents: Byetta, Trulicity, Victoza, Bydureon Bcise, Mounjaro.
Non-Preferred Agents: Ozempic, Rybelsus, Soliqua 100/33, Tanzeum, Xultophy 100/3.6.
LENGTH OF AUTHORIZATIONS: 1 year
Preferred Agents Clinical Criteria: Diagnosis of type II diabetes”^[8]

Authorization length for T2D: 1 year. For weight-loss GLP-1s: 6 months (initial), with BMI >40 threshold and step-therapy gates. The T2D class does NOT require the BMI >40 floor — a T2D member with BMI 28 can access Ozempic (after PA) or Mounjaro (after preferred-agent step-therapy) without triggering the weight-loss pathway gates.

Prescribers filing a PA for a patient with both T2D and obesity must identify the correct indication pathway. Filing under the weight-loss pathway when the medical indication is T2D — or vice versa — will route the claim to the wrong SA form and criteria.

Five MCOs, one Common Core Formulary, six PBMs (for now)

As of July 1, 2025, Virginia Cardinal Care contracts with five MCOs.^[17] Humana Healthy Horizons of Virginia replaced Molina Complete Care of Virginia on that date; Molina members were auto-transitioned to Humana. Anthem HealthKeepers Plus also administers the Foster Care Specialty Plan (FCSP) statewide.

All five MCOs operate on the same DMAS Common Core Formulary for the GLP-1 weight management and T2D Incretin Mimetics classes. Per the PDL header:

“Virginia’s Medicaid Preferred Drug List (PDL) / Common Core Formulary only includes select drug classes, other classes will pay such as but not limited to diuretics, many cardiac agents, many antibiotics etc.”^[8]

The Weight Management Agents CLOSED CLASS uniformly lists Wegovy, Zepbound, and Saxenda as Non-Preferred, with SA required and PA criteria anchored to the statewide DMAS SA forms. Individual MCO formularies may add Tier 2 brand-status flags or additional quantity-limit annotations, but cannot impose stricter criteria within the closed class than the statewide DMAS rule.

All SA forms are submitted through the DMAS VAMPS portal at virginiamedicaidpharmacyservices.com, faxed to 800-932-6651, or phoned to 800-932-6648 — regardless of which MCO the member is enrolled in. Prime Therapeutics Management LLC processes FFS PA submissions. MCO members’ PA submissions are routed through the VAMPS portal which feeds to the appropriate MCO PBM.

After the July 1, 2026 HB 2610 consolidation, all pharmacy claims (FFS and MCO) will route to the single PAHP PBM. Members should verify current submission instructions after that date with their MCO or the VAMPS portal.

How Virginia compares to the prior 17 states in this series

Virginia adds a configuration the series had not seen before: a state where GLP-1 coverage for weight loss is real, positive, and enforced by primary-source SA forms, but with a BMI floor that excludes the majority of the FDA-eligible patient population.

The KFF binary “covers” classification correctly places both NC and VA in the positive-coverage column — but the operational access gap is wide. A member with BMI 32 and hypertension qualifies under NC, TN, and the FDA label. The same member in Virginia does not qualify for the weight-loss pathway, and would need BMI >40 or BMI >37+comorbidity to qualify under Virginia Cardinal Care.

Excluded populations and coverage limits

• BMI 27–39 with comorbidities (weight-loss pathway): Not covered under the weight-loss management pathway regardless of comorbidity burden. The BMI >40 (or BMI >37+specific comorbidities) floor is absolute in the current SA form.
• Concurrent GLP-1 use: Members “not concurrently on another GLP-1 receptor agonist” — exclusion applies across all three SA form pathways (weight-loss, MACE, MASH).
• Pregnancy and lactation: Excluded (orlistat exclusion clause); GLP-1s also contraindicated in pregnancy.
• Active eating disorder: “No history of an eating disorder (e.g., anorexia, bulimia)” required.
• Personal or family history of MTC or MEN2: Excluded for GLP-1 RAs (standard FDA label contraindication).
• Active pancreatitis; acute suicidal behavior/ideation: Excluded.
• BMI below 25 at renewal: “Renewals will no longer be granted once a member reaches a BMI < 25” — a hard renewal ceiling.
• MASH patients with HbA1c >9.5% or MELD >12 or hepatic decompensation: Excluded from the MASH pathway.
• MACE patients with diabetes: Excluded from the MACE pathway (cardiovascular risk-reduction SA form explicitly requires “member does not have a previous diagnosis of diabetes”).

Patient action steps and appeal pathway

If you are a Virginia Cardinal Care member seeking Wegovy, Zepbound, or Saxenda for weight management, the following steps apply:

1. Confirm your BMI threshold. Check whether your BMI exceeds 40 (no comorbidities required) or exceeds 37 with at least one of: dyslipidemia, hypertension, or type 2 diabetes. If your BMI is below 37, the weight-loss pathway is not available under current rules — but the MACE or MASH pathways may apply (see your prescriber to determine eligibility).
2. Document your step-therapy history. Your prescriber must document a trial of a non-GLP-1 weight-loss drug (phentermine, phendimetrazine, benzphetamine, diethylpropion, phentermine/topiramate, or orlistat) for the required trial period, or document intolerance to all options. If you previously took Saxenda, document that trial outcome (6 months, <5% body weight reduction).
3. Identify your Cardinal Care MCO. As of July 1, 2025, the five MCOs are Aetna Better Health of Virginia, Anthem HealthKeepers Plus, Humana Healthy Horizons of Virginia, Sentara Health Plans, and UnitedHealthcare Community Plan VA. If you are not in managed care, you are in the FFS population (Prime Therapeutics).
4. Submit the SA form through VAMPS. The current form is the Virginia DMAS SA Form: Weight-Loss Management (Effective 07/31/2025). Fax to 800-932-6651, call 800-932-6648 for urgent requests, or submit via the VAMPS portal at virginiamedicaidpharmacyservices.com.
5. If denied at the MCO level, file an internal MCO appeal. Document your appeal in writing and retain all correspondence.
6. If denied after MCO appeal, file with the DMAS Appeals Division within 120 days of the MCO’s final appeal decision:
   DMAS Appeals Division
   600 E Broad St, Richmond VA 23219
   Phone: 804-371-8488 (TTY: 1-800-828-1120)
   Fax: 804-452-5454
   Email: appeals@dmas.virginia.gov
   Online: dmas.virginia.gov/appeals/
7. Exception under 42 CFR § 438.402. In some circumstances (e.g., MCO failed to act within the required time frame), you may be able to file directly with DMAS without exhausting the MCO internal appeal. Consult the DMAS appeals page or a patient advocate for eligibility under this exception.

PA approval is not guaranteed even when clinical criteria are met. “Submission of documentation does NOT guarantee coverage by the Department of Medical Assistance Services,” per the SA form verbatim.^[1]

Related research

• North Carolina Medicaid GLP-1 coverage (Pattern #9) — the closest analog to Virginia in the series: both are KFF January 2026 covering states, but NC uses an FDA-label-aligned BMI ≥30 threshold vs. Virginia’s BMI >40 floor.
• Tennessee Medicaid GLP-1 coverage (Pattern #13) — the most permissive covering state: FDA-label-aligned BMI thresholds, 10-AOM no-PA panel, no separate Saxenda step-therapy gate. Represents the opposite end of the coverage-restriction spectrum from Virginia.
• GLP-1 pricing index — Virginia’s active 2026 SB30 legislation includes a $245/month price target that would trigger threshold expansion if achieved; the pricing index documents live telehealth pricing against that benchmark.
• GLP-1 insurance dropped coverage appeal playbook — structured appeal tactics, including how to use adjudication-error arguments at state fair hearings.
• State Medicaid GLP-1 coverage hub — full 50-state index with pattern taxonomy and last-verified dates.